Advaita selected to participate in Michigan I-Corps program starting May 2013 Advaita.
While understanding gained from grant-supported basic research advances a specific field of technology or engineering frequently, clinically-relevant results show immediate prospect of broader applicability and improved patient care. Such results could be translated through I-Corps into technology with near-term benefits for the economy and society. With these goals at heart, Advaita plans to handle the need for more streamlined drug-discovery strategies that will save money and time for the educational and pharmaceutical industries. By leveraging Pathway-Guide's unique capability to more efficiently target particular genes implicated in an illness or disease treatment, the company shall commercialize a technology benefitting both the Michigan economy and our society as a whole..‘Psoriasis itself increases depressive disorder and suicides.’ Assuming the drug is approved by the U.S. Food and Drug Administration, Lebwohl said it will likely be expensive. For comparison purposes, Stelara would price from $30,000 to $70,000 a full year without insurance, based on the National Psoriasis Foundation. The other study, funded by drug maker Novartis, involved a lot more than 600 patients with psoriatic arthritis. Individuals received either Cosentyx or a placebo drug. About 50 % of the patients taken care of immediately treatment with Cosentyx, weighed against a bit more than 17 % of patients receiving placebo, researchers found. ‘We have a very important new asset to take care of psoriatic arthritis,’ said lead researcher Dr.